HUMAN ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX
Sickle Cell Disease (SCD)
Yves Pastoreprotein_peptidePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Sickle Cell Disease (SCD) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Medroxyprogesterone acetate University of Pennsylvania | Phase 4 | BB |
Tarperprumig Alexion Pharmaceuticals, Inc. | Phase 2 | CCC |
Same molecule, other indications
HUMAN ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →